Medicinal composition containing IncRNA inhibitor and application thereof

A technology of inhibitors and compositions, applied in the field of pharmaceutical compositions containing lncRNA inhibitors to prevent or treat heart diseases, can solve the problem that the pathogenesis of heart diseases is not completely clear, and the prevention, diagnosis and treatment of heart diseases cannot be satisfactory effect and other issues, to achieve the effect of wide application range, simple preparation process and friendly application environment

Active Publication Date: 2015-04-29
QINGDAO UNIV
View PDF1 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the pathogenesis of heart disease is not completely clear, and the prevention, diagnosis and treatment of heart disease cannot achieve satisfactory results. It is urgent to develop new drugs for the diagnosis and prevention of heart disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing IncRNA inhibitor and application thereof
  • Medicinal composition containing IncRNA inhibitor and application thereof
  • Medicinal composition containing IncRNA inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] The pharmaceutical composition of this embodiment includes a lncRNA inhibitor and a pharmaceutically acceptable carrier; the nucleotide sequence of the lncRNA inhibitor used is shown in the following SEQ ID NO: 1: 5'-AGUGAGGUAGUCUCACAA-3'; the carrier is One or more of chitosan, cholesterol, nanoparticles and liposomes; the content of the lncRNA inhibitor in the pharmaceutical composition is 0.5-1 gram.

[0019] The lncRNA inhibitor pharmaceutical composition of the present invention is administered orally or injected, and is used for the treatment and prevention of myocardial infarction, myocardial ischemia injury and myocardial fibrosis.

Embodiment 2

[0021] Detection of lncRNA expression during myocardial ischemia and cardiomyocyte hypoxia-induced cardiomyocyte apoptosis. In this example, for the cardiomyocyte apoptosis experimental model, conventional methods were used to cultivate rat neonatal rat primary cardiomyocytes in a hypoxic incubator. (Oxygen concentration is lower than 1%) cultured for different time, extract RNA, real-time fluorescent quantitative PCR technology detects the expression level of lncRNA, figure 1 It is a graph showing the change of lncRNA expression level in the myocardial cell apoptosis process of myocardial ischemia injury and hypoxia treatment (Anoxia), wherein figure 1 A shows the expression level of lncRNA in primary cardiomyocytes under hypoxia treatment; figure 1 B shows the expression level of lncRNA in mouse myocardial ischemia injury; it is significantly up-regulated within 4h-8h of hypoxia treatment ( figure 1 A); The myocardial ischemia model was established by ligation of the corona...

Embodiment 3

[0023] In the experiment of lncRNA inhibitors inhibiting cardiomyocyte apoptosis, primary cultured cardiomyocytes were used as a model in this example, and lncRNA inhibitor nucleotides were transfected (the lncRNA inhibitor nucleotide sequence is completely reversed to a coding sequence of lncRNA Complementary sequence, 5'-CAGUGAGGUAGUCUCACAA-3', combined with lncRNA to inhibit the expression of lncRNA), after 24 hours of transfection, the treated cells were cultured in a hypoxic incubator for 3 hours to induce apoptosis, trypan blue staining method Detect cardiomyocyte apoptosis, the results are shown in figure 2 ,in figure 2 A indicates that primary cardiomyocytes were transfected with an lncRNA inhibitor (anta-lncRNA) to inhibit the expression of endogenous lncRNA; figure 2 B represents the effect on hypoxia-induced cardiomyocyte apoptosis, and NC was transfected as a negative control. figure 2 It was shown that inhibiting endogenous lncRNA can significantly inhibit h...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicinal composition containing an IncRNA inhibitor and an application thereof. The medicinal composition comprises the IncRNA inhibitor and a vector, wherein the nucleotide sequence of the IncRNA inhibitor is 5'-CAGUGAGGUAGUCUCACAA-3'; the vector is one or more of chitosan, cholesterol, nano particles and lipidosome. The content of the IncRNA inhibitor in the medicinal composition is 0.5-1g. The medicinal composition is used for treating and preventing myocardial infarction, myocardial ischemial injury and myocardial fibrosis. The medicinal composition has the advantages that the selected materials are scientific and reasonable, the preparation process is simple, the medicinal action is obvious, the use range is wide, the safe and reliable effects are achieved and the medicinal composition is friendly to the application environment.

Description

Technical field: [0001] The invention belongs to the technical field of biomedicine, and relates to a short nucleotide novel drug and its application, in particular to a pharmaceutical composition containing an lncRNA inhibitor and its application in preventing or treating heart disease. Background technique: [0002] Cardiovascular disease is the main threat to human health and life, and is the number one killer of human health. More than 17 million people die from cardiovascular disease in the world every year, and its mortality rate is close to the sum of all cancer mortality rates. With the improvement of human living standards and the change of diet structure, the mortality rate of cardiovascular disease is on the rise, surpassing cancer as the number one cause of death. According to the latest statistical results released recently, the prevalence of hypertension among residents aged 18 and above is 18.8%, and it is estimated that the number of patients in the country i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K31/7088A61P9/10A61P9/00
Inventor 王昆李培峰周露玙赵文科赵兵
Owner QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap